Neurogene (NASDAQ:NGNE) Stock Rating Raised to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Neurogene (NASDAQ:NGNE – Free Report) from a strong sell rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.

A number of other equities analysts also recently issued reports on the stock. HC Wainwright dropped their price objective on shares of Neurogene from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Tuesday, November 10th. Guggenheim upped their price objective on Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, October 15th. JPMorgan Chase & Co. initiated coverage on Neurogene in a report on Thursday, October 8th. They issued an “overweight” rating and a $60.00 target price on the stock. Finally, William Blair raised Neurogene to a “strong-buy” rating in a report on Wednesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Neurogene currently has an average rating of “Buy” and an average target price of $79.57.

View Our Latest Research Report on Neurogene

Neurogene Stock Up 0.1%

NASDAQ:NGNE traded up $0.03 on Friday, hitting $23.93. The stock had a trading volume of 193,615 shares, compared to its average volume of 312,797. The stock has a market cap of $495.35 million, a price-to-earnings ratio of -4.70 and a beta of 1.75. The business’s 50-day simple moving average is $28.21 and its two-hundred day simple moving average is $28.08. Neurogene has a 52-week low of $15.93 and a 52-week high of $43.66.

Neurogene (NASDAQ:NGNE – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.31. As a group, equities research analysts anticipate that Neurogene will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Neurogene

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in shares of Neurogene during the 2nd quarter valued at $904,000. BlackRock Inc. bought a new position in Neurogene in the 2nd quarter worth $33,274,000. Renaissance Technologies LLC boosted its holdings in Neurogene by 210.0% in the 1st quarter. Renaissance Technologies LLC now owns 43,400 shares of the company’s stock worth $875,000 after buying an additional 29,400 shares during the period. Wellington Management Group LLP bought a new position in Neurogene in the 2nd quarter worth $987,000. Finally, Deutsche Bank AG purchased a new stake in Neurogene in the 2nd quarter worth $3,354,000. Institutional investors own 52.37% of the company’s stock.

More Neurogene News

Here’s some of the latest news about NGNE:

  • Positive Sentiment: HC Wainwright raised its 2026 and 2027 earnings-per-share estimates, projecting narrower losses across the periods and lifting its FY2027 estimate to a loss of $4.80 per share from $4.99. The firm maintained its Buy rating and $60 price target. HC Wainwright forecast for Neurogene
  • Positive Sentiment: Canaccord Genuity also reaffirmed its Buy rating on Neurogene, signaling continued analyst confidence. Canaccord Genuity keeps Buy rating
  • Negative Sentiment: Despite the improved estimates, HC Wainwright still expects Neurogene to report losses in 2026 and 2027, underscoring its ongoing financial risk.

About Neurogene

(Get Free Report)

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.

Featured Articles

Analyst Recommendations for Neurogene (NASDAQ:NGNE)

Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.